These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 37660479)
21. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887 [TBL] [Abstract][Full Text] [Related]
22. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate. Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967 [TBL] [Abstract][Full Text] [Related]
23. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
24. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861 [TBL] [Abstract][Full Text] [Related]
26. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer. Pan LN; Ma YF; Li Z; Hu JA; Xu ZH Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140 [TBL] [Abstract][Full Text] [Related]
28. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations]. Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737 [TBL] [Abstract][Full Text] [Related]
29. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500 [TBL] [Abstract][Full Text] [Related]
30. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038 [TBL] [Abstract][Full Text] [Related]
31. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521 [TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. Chen W; Li L; Cheng S; Yu J Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356 [TBL] [Abstract][Full Text] [Related]
33. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression]. Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196 [TBL] [Abstract][Full Text] [Related]
35. Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South Korea. Jung HA; Lee DH; Lim SM; Yu H; Yoon S; Kim D; Kim KP; Jeong H; Doh H; Lim S; Kim J; Zhao X; Horsburgh D; Patel D; Kim JA; Toh KC JAMA Netw Open; 2024 Feb; 7(2):e2355331. PubMed ID: 38334998 [TBL] [Abstract][Full Text] [Related]
36. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053 [TBL] [Abstract][Full Text] [Related]
37. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. Zhang X; Han X; Zuo P; Zhang X; Xu H J Int Med Res; 2020 Sep; 48(9):300060520959478. PubMed ID: 32993395 [TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796 [TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Ji M; Liu Y; Li Q; Li X; Ning Z; Zhao W; Shi H; Jiang J; Wu C Cancer Biol Ther; 2016 Apr; 17(4):407-13. PubMed ID: 26954523 [TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]